Taro Pharmaceutical Industries (Taro Pharmaceutical Industries) EBIT per Share : $1.16 (TTM As of Dec. 2023)

View and export this data going back to 1987. Start your Free Trial

What is Taro Pharmaceutical Industries EBIT per Share?

Taro Pharmaceutical Industries's EBIT per Share for the three months ended in Dec. 2023 was $0.42. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $1.16.

During the past 12 months, the average EBIT per Share Growth Rate of Taro Pharmaceutical Industries was -26.00% per year. During the past 3 years, the average EBIT per Share Growth Rate was -58.10% per year. During the past 5 years, the average EBIT per Share Growth Rate was -38.30% per year. During the past 10 years, the average EBIT per Share Growth Rate was -19.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Taro Pharmaceutical Industries's EBIT per Share or its related term are showing as below:

TARO' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -58.1 Med: 29.9 Max: 87.9
Current: -58.1

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Taro Pharmaceutical Industries was 87.90% per year. The lowest was -58.10% per year. And the median was 29.90% per year.

TARO's 3-Year EBIT Growth Rate is ranked worse than
95.65% of 850 companies
in the Drug Manufacturers industry
Industry Median: 7.95 vs TARO: -58.10

Taro Pharmaceutical Industries's EBIT for the three months ended in Dec. 2023 was $15.9 Mil.

Taro Pharmaceutical Industries EBIT per Share Historical Data

The historical data trend for Taro Pharmaceutical Industries's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Taro Pharmaceutical Industries EBIT per Share Chart

Taro Pharmaceutical Industries Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

EBIT per Share

Get a 7-Day Free Trial

9.16

7.77

-10.20

2.11

1.05

Taro Pharmaceutical Industries Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT per Share	Get a 7-Day Free Trial															0.03	0.83	-0.21	0.13	0.42

Taro Pharmaceutical Industries EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Taro Pharmaceutical Industries's EBIT per Share for the fiscal year that ended in Mar. 2023 is calculated as

	EBIT per Share		(A: Mar. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	39.466	/	37.585
=	1.05

Taro Pharmaceutical Industries's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	15.883	/	37.585
=	0.42

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.16

Taro Pharmaceutical Industries (NYSE:TARO) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Taro Pharmaceutical Industries EBIT per Share Related Terms

Thank you for viewing the detailed overview of Taro Pharmaceutical Industries's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Taro Pharmaceutical Industries (Taro Pharmaceutical Industries) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Taro Pharmaceutical Industries Ltd (NYSE:TARO) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

TAL:Germany

Address

14 Hakitor Street, P.O. Box 10347, Haifa Bay, Haifa, ISR, 2624761

Website

https://www.taro.com

Taro Pharmaceutical Industries Ltd produces, researches, develops, and markets pharmaceutical products. Its primary focus includes semi-solid formulations, such as creams and ointments, and other dosage forms such as liquids, capsules, and tablets. The company is engaged in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. Geographically, it derives a majority of its revenue from the United States and also has a presence in Canada, Israel, and Other Countries.

Executives

Sun Pharma Global Inc	10 percent owner
Sun Pharmaceutical Industries Ltd	10 percent owner, other: Affiliated Party	17/B, MAHAL INDUSTRIAL ESTATE, MAHAKALI CAVES ROAD, ANDEHERI (EAST) K7 400 093
Alkaloida Chemical Co Exclusive Group Ltd.	10 percent owner	KABAY JANOS UT 29., TISZAVASVARI K5 4440
Franklin Resources Inc	10 percent owner	FRANKLIN RESOURCES INC, ONE FRANKLIN PARKWAY, SAN MATEO CA 94403